122 related articles for article (PubMed ID: 23106957)
1. In vitro characterization of the oxidation of a pyridinium metabolite of haloperidol by human placenta: the effect of smoking.
Fang J; Song J
J Pharm Pharm Sci; 2012; 15(4):538-47. PubMed ID: 23106957
[TBL] [Abstract][Full Text] [Related]
2. In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes.
Fang J; McKay G; Song J; Remillrd A; Li X; Midha K
Drug Metab Dispos; 2001 Dec; 29(12):1638-43. PubMed ID: 11717183
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites.
Avent KM; DeVoss JJ; Gillam EM
Chem Res Toxicol; 2006 Jul; 19(7):914-20. PubMed ID: 16841959
[TBL] [Abstract][Full Text] [Related]
4. Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes.
Usuki E; Pearce R; Parkinson A; Castagnol N
Chem Res Toxicol; 1996 Jun; 9(4):800-6. PubMed ID: 8831826
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway.
Kalgutkar AS; Taylor TJ; Venkatakrishnan K; Isin EM
Drug Metab Dispos; 2003 Mar; 31(3):243-9. PubMed ID: 12584149
[TBL] [Abstract][Full Text] [Related]
6. Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP.
Igarashi K; Kasuya F; Fukui M; Usuki E; Castagnoli N
Life Sci; 1995 Nov; 57(26):2439-46. PubMed ID: 8847965
[TBL] [Abstract][Full Text] [Related]
7. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.
Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L
J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460
[TBL] [Abstract][Full Text] [Related]
8. In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol.
Pan LP; De Vriendt C; Belpaire FM
Pharmacogenetics; 1998 Oct; 8(5):383-9. PubMed ID: 9825830
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
[TBL] [Abstract][Full Text] [Related]
10. Tobacco smoke-dependent changes in cytochrome P450 1A1, 1A2, and 2E1 protein expressions in fetuses, newborns, pregnant rats, and human placenta.
Czekaj P; Wiaderkiewicz A; Florek E; Wiaderkiewicz R
Arch Toxicol; 2005 Jan; 79(1):13-24. PubMed ID: 15448981
[TBL] [Abstract][Full Text] [Related]
11. Involvement of CYP3A4 in the metabolism of bromperidol in vitro.
Sato S; Someya T; Shioiri O; Koitabashi T; Inoue Y
Pharmacol Toxicol; 2000 Mar; 86(3):145-8. PubMed ID: 10752674
[TBL] [Abstract][Full Text] [Related]
12. Identification of an N-methyl-4-phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event.
Kalgutkar AS; Nguyen HT
Drug Metab Dispos; 2004 Sep; 32(9):943-52. PubMed ID: 15319335
[TBL] [Abstract][Full Text] [Related]
13. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
14. In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol.
Pan L; Belpaire FM
Eur J Clin Pharmacol; 1999 Oct; 55(8):599-604. PubMed ID: 10541779
[TBL] [Abstract][Full Text] [Related]
15. CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes.
Tateishi T; Watanabe M; Kumai T; Tanaka M; Moriya H; Yamaguchi S; Satoh T; Kobayashi S
Life Sci; 2000 Nov; 67(24):2913-20. PubMed ID: 11133003
[TBL] [Abstract][Full Text] [Related]
16. Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: evaluation of possible mechanisms.
Eyles DW; Stedman TJ; Pond SM
Psychopharmacology (Berl); 1994 Oct; 116(2):161-6. PubMed ID: 7862945
[TBL] [Abstract][Full Text] [Related]
17. The effect of cigarette smoking on drug metabolism in the liver and placenta: the use of cotinine in verifying smoking status.
Pasanen M; Vahakangas K; Sotaniemi EA; Pelkonen O
Eur J Drug Metab Pharmacokinet; 1988; 13(1):41-5. PubMed ID: 3396613
[TBL] [Abstract][Full Text] [Related]
18. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver.
Burke MD; Thompson S; Weaver RJ; Wolf CR; Mayer RT
Biochem Pharmacol; 1994 Aug; 48(5):923-36. PubMed ID: 8093105
[TBL] [Abstract][Full Text] [Related]
20. Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes.
Shiraga T; Kaneko H; Iwasaki K; Tozuka Z; Suzuki A; Hata T
Xenobiotica; 1999 Mar; 29(3):217-29. PubMed ID: 10219963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
